325 related articles for article (PubMed ID: 24102067)
41. Modeling and simulation of biopharmaceutical performance.
Zhang X; Lionberger RA
Clin Pharmacol Ther; 2014 May; 95(5):480-2. PubMed ID: 24747237
[TBL] [Abstract][Full Text] [Related]
42. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
Breslow LH
Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
[TBL] [Abstract][Full Text] [Related]
43. Research, regulation and development of new pharmaceuticals: past, present and future. II.
Lasagna L
Am J Med Sci; 1972 Feb; 263(2):66-78. PubMed ID: 5017858
[No Abstract] [Full Text] [Related]
44. International Cooperation on Harmonisation of Technical Requirements for Approval of Veterinary Medicinal Products (VICH); final guidance for industry on "studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing" (VICH GL23); availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2002 Jan; 67(3):602-3. PubMed ID: 12358039
[TBL] [Abstract][Full Text] [Related]
45. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
Zolnik BS; Sadrieh N
Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
[TBL] [Abstract][Full Text] [Related]
46. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
47. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
Lanthier M; Miller KL; Nardinelli C; Woodcock J
Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
[TBL] [Abstract][Full Text] [Related]
48. Innovative fluorine-addition process could enable faster drug design and manufacture.
Future Med Chem; 2009 Sep; 1(6):1028. PubMed ID: 21545053
[No Abstract] [Full Text] [Related]
49. International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Jul; 66(135):36791-2. PubMed ID: 12356097
[TBL] [Abstract][Full Text] [Related]
50. Proposed accelerated FDA approvals for special medical use.
Somberg JC
Am J Ther; 2012 Nov; 19(6):393-4. PubMed ID: 23154227
[No Abstract] [Full Text] [Related]
51. Pharmaceuticals and medical devices: FDA oversight.
; Berry MD
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
[No Abstract] [Full Text] [Related]
52. International Cooperation on Harmonisation of Technical requirements for Approval of Veterinary Medicinal Products (VICH); final guidance on " Safety studies for veterinary drug residues in human food: reproduction toxicity testing" (VICH GL22); availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2002 Jan; 67(3):603-5. PubMed ID: 12365425
[TBL] [Abstract][Full Text] [Related]
53. The drug lag: new drug introductions in India in comparison to United States.
Karan RS; Malhotra S; Pandhi P
J Assoc Physicians India; 2002 Jun; 50():782-7. PubMed ID: 12240842
[TBL] [Abstract][Full Text] [Related]
54. The role of fluorine in medicinal chemistry.
Shah P; Westwell AD
J Enzyme Inhib Med Chem; 2007 Oct; 22(5):527-40. PubMed ID: 18035820
[TBL] [Abstract][Full Text] [Related]
55. Clinical and regulatory features of drugs not initially approved by the FDA.
Wang B; Avorn J; Kesselheim AS
Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
[TBL] [Abstract][Full Text] [Related]
56. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
57. A long and winding road; evolution of antimicrobial drug development - crisis management.
Echols RM
Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1311-9. PubMed ID: 23241188
[TBL] [Abstract][Full Text] [Related]
58. Controlling conformations of conjugated polymers and small molecules: the role of nonbonding interactions.
Jackson NE; Savoie BM; Kohlstedt KL; Olvera de la Cruz M; Schatz GC; Chen LX; Ratner MA
J Am Chem Soc; 2013 Jul; 135(28):10475-83. PubMed ID: 23800150
[TBL] [Abstract][Full Text] [Related]
59. Issues in bringing new drugs to the market.
Tracey WR
Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329172
[No Abstract] [Full Text] [Related]
60. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
